Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD. Jeffrey D. Dunn ...

Please provide your email address to receive an email when new articles are posted on . Initiating single-inhaler triple therapy for COPD, compared with multiple-inhaler triple therapy, resulted in ...

The IMPACT and ETHOS trials showed that single-inhaler triple therapy significantly reduce the rate of COPD exacerbation and mortality compared with dual bronchodilators. Findings are from an ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...

Please provide your email address to receive an email when new articles are posted on . Compared with a dual therapy inhaler, a triple therapy inhaler improved inspiratory capacity in those with COPD.

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...

Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...